Is Green Organic Dutchman (TSX:TGOD) a Steal at $2?

Green Organic Dutchman Holdings Ltd (TSX:TGOD) may be coming off a bad month, but that doesn’t mean it’s become a cheap buy.

Marijuana plant and cannabis oil bottles isolated

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Green Organic Dutchman Holdings (TSX:TGOD) had a very bad month of September, declining around 40%. You know it’s bad when CannTrust, a company that had its licence suspended, didn’t have as big of a drop during the month. TGOD finished September at just over $2 a share, as it hit a new 52-week low.

Why have investors been down on the stock?

While investors as a whole haven’t been very excited about cannabis stocks lately, TGOD’s decline has been notably worse. And the reason it has done so much worse is that early on in the month, when the stock was trading around $3.50, we learned that Aurora Cannabis had sold its shares in TGOD at a price of just $3.

As a result, the sale flooded the market and created a huge sell-off of TGOD stock. Inevitably, what ends up happening then is that triggers even more selling, as technical indicators tell other investors to sell while stop-losses also cause more shares to be sold along the way.

It created a perfect storm for which there was no way for TGOD to pull itself out.

Has the stock become a cheap buy?

Despite the heavy selling, TGOD’s stock hasn’t been in oversold during the month. Its Relative Strength Index (RSI), which measures the stock’s gains and losses over a 14-day period, was above 30 during the whole month of September and finished the month just above the mark. Once it falls below 30, the stock is considered to be oversold.

With the stock almost oversold and at a 52-week low, it could entice investors to buy the stock at what could be perceived as a cheap price. The problem is that for the amount of revenue that the company has generated, it’s still trading at a hefty premium.

Over the last 12 months, TGOD has generated just over $7 million in sales. With a market cap of around $560 million, that means investors are paying close to 80 times sales. By comparison, Canopy Growth was trading at a price-to-sales ratio of 36 at the close of the month. It’s hard to justify TGOD being at a more significant multiple than the top pot stock in the country.

And with the company consistently producing losses, it’s hard to say that TGOD is any better than its peers in that regard.

How TGOD could rally

What could save the company is a strong quarter that shows either significant sales growth or TGOD getting close to breaking even. While the latter may seem like a long shot, the good news is that the company says that shipments it has sent to the Ontario Cannabis Store have had very good feedback, and that there’s strong demand for the company’s premium cannabis products. With TGOD finally ready to make a splash in the recreational market, it could be what it needs to pull itself out of this tailspin.

Ultimately, it’ll come down to how strong the numbers look like. Until TGOD can demonstrate some sort of progress, it’ll be hard to get investors excited about a stock that’s been in a free fall. And it may take a couple of quarters before investors are able to see just how strong those numbers really are.

Bottom line

In short, no, TGOD is still not a good buy even at $2 a share. While the company claims it is seeing some positive results, investors need to be able to see that for themselves on the company’s financials, and that’s when we might see the stock finally rally.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor David Jagielski has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »